How to Win at the Partnering Game

October 23 and November 14, 2013

An Overview of Biotech and Pharmaceutical Partnering with Facts, Fallacies, and Tips

In this ShareVault webinar, Linda Pullan will provide an overview of biotech and pharmaceutical partnering. Join us for a review of the rules of the partnering game –whether it’s partnering from preclinical to late clinical development – to provide an understanding of what to expect in moving from introductions to negotiations of a license or acquisition and how to win with a clear strategy. If you are thinking about doing a deal, this overview should be helpful and fun.

Learning Objectives:
  • Consider when to partner
  • Know what to expect in the partnering process
  • What your partnering strategy should include
  • Common misconceptions

Speaker Biography:
Linda M. Pullan, Ph.D. offers biotech and pharmaceutical companies consulting in all aspects of partnering through Pullan Consulting (www.pullanconsulting.com). Linda has a Ph.D. in Biochemistry and a B.S. in Chemistry. Linda has more than 20 years of drug industry experience, beginning in drug discovery at Monsanto/Searle/now Pfizer and ICI/Zeneca/now AstraZeneca. After doing licensing at what is now AstraZeneca, Dr. Pullan continued as head of oncology and hematology licensing for Amgen. She then joined Kosan Biosciences as VP of Business Development and experienced all the tasks of out-licensing and business development in a small company. For several years, she has been providing companies help in identification, evaluation, valuation, negotiation and strategy for partnering in or out. She has an extensive deal sheet ranging from company acquisitions to Phase III compounds and from preclinical candidates to technologies, with both in- and out-licensing. She writes a free monthly newsletter Pullan's Pieces, with tidbits of science and business for about 3,600 readers. Interested readers may sign up by sending an email to linda@pullanconsulting.com.